GalenusRx
GalenusRx is a medication safety technology company that offers the APPRAISE platform, using predictive algorithms to analyze drug-drug, drug-gene, and drug-disease interactions for personalized risk assessment, serving health systems, payers, ACOs, pharmaceutical companies, and consumers via subscription.
- Company typePrivate
- Founded2023
- HeadquartersFernandina Beach, United States
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
What GalenusRx does
GalenusRx, Inc. is a privately held healthcare technology company founded in 2023 and headquartered in Montverde, Florida (incorporated in Delaware). The company develops and commercializes the APPRAISE (Actionable PolyPharmacy Risk Assessment Index for Safety and Efficacy) platform, a proprietary medication safety system that uses quasi-mechanistic predictive algorithms to simultaneously analyze drug-drug, multi-drug, drug-gene, and drug-disease interactions, producing personalized risk assessments individualized to a patient's DNA profile. APPRAISE is delivered primarily through a subscription service called Lifesaving Insights, which combines pharmacogenomic (PGx) testing — an at-home cheek swab analyzing approximately 100 gene variants — with consultations from Precision Clinical Pharmacists who generate tailored medication recommendations.
The company operates a dual-channel go-to-market: enterprise field sales targeting health systems, ACOs, payers, reinsurance intermediaries, pharmaceutical companies, and hospice providers, alongside a direct-to-consumer motion through the company website. Distribution is augmented by strategic channel partnerships with Hannover Re US (reinsurance), healthŌme (PGx testing), Kadance (pharmacogenomics ecosystem), and the Florida Association of ACOs (ACO network). Pricing is subscription-based on an annual billing cadence, with no publicly disclosed price points; enterprise contracts appear to be quote-based.
The business is led by founders Jacques Turgeon (CEO & CSO) and Veronique Michaud (President & COO), both internationally recognized pharmacotherapy researchers with combined $92M+ in research funding and 300+ peer-reviewed publications, alongside co-founder Peter Panageas (CSO/Commercial), Co-CEO Calvin H. Knowlton, Co-Founder Orsula Knowlton, and an advisory board of approximately 9 members including former FDA Office of Clinical Pharmacology Director Lawrence Lesko. The company has raised approximately $8 million across SEC Form D exempt securities offerings in 2024 and 2026, and was awarded an NIH SBIR grant in November 2025. GalenusRx maintains HIPAA compliance and has earned recognition including USA TODAY Network's 2024 Florida Startups to Watch.
GalenusRx firmographics
Firmographics- Name
- GalenusRx
- Legal name
- GalenusRx, Inc.
- Website
- https://galenusrx.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GalenusRx is a medication safety technology company that offers the APPRAISE platform, using predictive algorithms to analyze drug-drug, drug-gene, and drug-disease interactions for personalized risk assessment, serving health systems, payers, ACOs, pharmaceutical companies, and consumers via subscription.
- Ownership category
- akta.pro rank
GalenusRx industry classification
Industry- Product category
- Medication Safety Analytics
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Pharmacogenomics (PGx) Decision Support (HLAAANAB)
- akta.pro secondary industries
- Medication Safety, Pharmacovigilance & Adverse Event Reporting IT (HLACAKAK), Medication Therapy Management (MTM) & Clinical Pharmacy Services Tools (HLACAKAH), Pharmacovigilance, Medication Safety & Controlled Substance Diversion Monitoring (HLAFALAN)
Keywords
Where GalenusRx is headquartered
LocationHeadquarters
- HQ city
- Fernandina Beach
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
GalenusRx business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Lifesaving Insights Subscription: Subscription-based technology and consulting service providing personalized medication safety assessments, PGx testing interpretation, and ongoing pharmacist consultations. B2B and B2C models depending on channel (direct consumers, health systems, payers, pharma).
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Subscription-based service; specific pricing tiers not publicly disclosed. |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels6 records
GalenusRx product offering
Product offeringCore offering
GalenusRx provides a proprietary medication safety assessment platform (APPRAISE) that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to deliver personalized risk scores individualized down to the DNA. Its Lifesaving Insights subscription service combines this platform with at-home pharmacogenomic (PGx) testing and Precision Clinical Pharmacist consultations to prevent adverse drug events, optimize medication regimens, and reduce polypharmacy-related hospitalizations across patients, providers, payers, ACOs, pharmaceutical companies, and hospices.
Product overview
GalenusRx is a medication safety organization offering a unified platform plus modules architecture centered on two core products: the APPRAISE Platform and Lifesaving Insights subscription service. APPRAISE is a proprietary medication safety assessment platform that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions using predictive algorithms individualized down to the DNA. Lifesaving Insights provides subscription-based pharmacogenomic testing and precision clinical pharmacist consultations. The company also offers targeted solutions for specific market segments including Patients and Consumers (with at-home PGx test kits), Providers and Health Systems, ACOs/Payers/Plan Sponsors, Pharmaceutical Companies (ADE Forecasting and Polypharmacy Engagement modules), Hospice Care, and CMS TEAMS Program.
Differentiator
Problem solved
Functional benefit
Brands
- APPRAISE: Actionable PolyPharmacy Risk Assessment Index for Safety and Efficacy - proprietary platform that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to provide comprehensive risk assessment individualized down to DNA.
- Lifesaving Insights
Products and services
- APPRAISE Platform Proprietary medication safety assessment platform that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions using quasi-mechanistic predictive algorithms to provide comprehensive risk assessments individualized down to the DNA. Targets health systems, payers, ACOs, pharmaceutical companies, and hospice providers.
- Lifesaving Insights Subscription-based technology and consulting service providing personalized pharmacogenomic assessments and data analysis from Precision Clinical Pharmacists, with tailored medication recommendations based on individual patient needs and goals. Offered through B2B and B2C channels.
- CMS TEAMS Program Solution Medication safety solution designed for CMS (Centers for Medicare & Medicaid Services) TEAMS program requirements, targeting medication therapy management for Medicare beneficiaries.
- Hospice Care Medication Safety Solution Predictive medication safety analytics and pharmacy solution for hospice providers combining advanced safety analytics with real-time Precision Clinical Pharmacist support for end-of-life medication planning.
- ADE Forecasting for Pharmaceutical Companies Cloud-based platform using predictive algorithms to virtually forecast adverse drug event risk for complex polypharmacy patients, providing insights to improve medication persistence and avoid regulatory actions.
- Personalized Comprehensive Polypharmacy Engagement Precision Clinical Pharmacist-led patient counseling service that virtually adds new drugs to individual medication regimens to support successful drug launches and ensure appropriate medication monitoring.
- Pharmacogenomic (PGx) Test Kit At-home cheek swab test kit analyzing approximately 100 gene variants that affect how the body interacts with specific medications, used to personalize medication safety assessments.
Quantifiable outcome
- 3:1 or greater ROI for value-based care clients
- +3 more outcomes
Companies that use GalenusRx
Customer profileNamed customers4 records
Segments4 records
Ideal customer profiles5 records
GalenusRx technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature4 records
GalenusRx partnerships and signals
Strategic signalPartnerships
Five partnerships are on record, tiered core and minor.
- Hesperos Inc.coreGalenusRx partnered with Hesperos Inc. through a Small Business Innovative Research (SBIR) grant awarded by the National Institute on Aging, part of the National Institutes of Health. The collaboration advances predictive models addressing anticholinergic concerns in aging populations.
- Florida Association of ACOs (FLAACOs)coreFLAACOs announced GalenusRx joined its network as a business partner, connecting GalenusRx with ACOs across Florida to equip them with solutions to identify high-risk patient cohorts and prevent adverse drug events, supporting ACO performance in 2025.
- Hannover Re UScoreHannover Life Reassurance Company of America partnered with GalenusRx to provide its healthcare division clients access to GalenusRx's personalized medication safety services. The partnership aims to help clients avoid preventable adverse drug events and reduce insured losses while improving quality and outcomes for policyholders in accountable care and value-based programs.
- healthŌmecoreStrategic partnership to launch a genomics-based personalized medication safety program combining pharmacogenomic testing and precision medication consultation to provide personalized medication support plans for healthŌme policyholders, targeting reduction in adverse drug events.
- KadanceminorKadance is listed as a partner on the GalenusRx Partners page. Kadance operates in the pharmacogenomics space and has partnerships including the acquisition of Kailos Genetics. The nature of the partnership with GalenusRx involves complementary pharmacogenomic and medication safety services.
Scale indicators4 records
Recent moves6 records
Expansion highlights7 records
GalenusRx competitors and assessment
Company assessmentDirect peers
- Tabula Rasa HealthCare: Operates MedWise, a medication safety and polypharmacy decision-support platform; the most direct competitor and the former employer of GalenusRx's two principal founders, with deeper EHR integration and an established payer and provider footprint.
- First Databank (FDB): Provides drug-interaction, drug-disease, and clinical decision support databases (MedKnowledge, PatientFirst) used by EHRs and pharmacy systems; comparable core function to APPRAISE in medication safety analytics, though without APPRAISE's genomic layer.
Broad incumbents
- Wolters Kluwer (Medi-Span): Drug data and clinical drug-reference vendor offering drug-interaction screening integrated into major EHRs; competes on the same medication safety decision-support surface but at much broader scale and as part of Wolters Kluwer's healthcare portfolio.
- Elsevier Clinical Solutions (ClinicalPath / ClinicalKey): Provides clinical decision support, drug reference, and care-pathway tools inside hospital workflows; overlaps with APPRAISE's clinical decision support capabilities within a much larger content and analytics portfolio.
- Lexicomp (Wolters Kluwer): Clinical drug information and interaction reference used by hospitals and pharmacists; competes for the same clinical-pharmacy decision-support budget and workflow integration as APPRAISE.
- Precision Medicine Group: Specialty services and data/analytics for pharma including real-world evidence and clinical trial enablement; comparable pharma-side customers and ADE/pharmacovigilance analytics use cases though at much broader scale and via services rather than GalenusRx's subscription platform.
Emerging players
- RxRevu (now Clarify): Prescription benefit decision support and analytics platform serving providers and payers; comparable pharmacy decision-support target customer and similar SaaS model, though not focused on the same genomic-polypharmacy niche.
- Kailos Genetics (a Kadance company): Pharmacogenomic testing services and partner/competitor in the PGx ecosystem; comparable patient-facing PGx offering and overlapping target customers for the consumer medication-safety pathway.
- DoseMe: Precision dosing software leveraging Bayesian and pharmacokinetic models for individual drug optimization; comparable 'individualized-to-the-patient' medication analytics niche and similar SaaS model targeting health systems and pharmacies.
Others
- PharmGKB (Stanford): Pharmacogenomics knowledge base providing curated drug-gene association evidence; not a commercial competitor but a foundational data source and ecosystem participant that powers and validates PGx decision support like APPRAISE.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
GalenusRx social profiles
Digital presenceGalenusRx compliance and trust
Trust signalCompliance1 record
GalenusRx financial estimates
Financial estimateRevenue estimate
Valuation estimate
GalenusRx leadership team
Management profileNumber of profiles
Profiles12 records
GalenusRx funding detail
Funding detailFunding overview
Funding rounds2 records
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GalenusRx M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GalenusRx
What does GalenusRx do?
GalenusRx provides a proprietary medication safety assessment platform (APPRAISE) that analyzes drug-drug, multi-drug, drug-gene, and drug-disease interactions to deliver personalized risk scores individualized down to the DNA. Its Lifesaving Insights subscription service combines this platform with at-home pharmacogenomic (PGx) testing and Precision Clinical Pharmacist consultations to prevent adverse drug events, optimize medication regimens, and reduce polypharmacy-related hospitalizations across patients, providers, payers, ACOs, pharmaceutical companies, and hospices.
Is GalenusRx a public or private company?
GalenusRx is a private company. It is classified as venture growth investor backed and is currently operating.
When was GalenusRx founded?
GalenusRx was founded in 2023. It employs 11 to 50 people.
Where is GalenusRx based?
GalenusRx is headquartered in Fernandina Beach, United States, in the North America region.
How does GalenusRx make money?
One revenue line is on record: lifesaving Insights Subscription.
Who are GalenusRx's main competitors?
Direct peers on record are Tabula Rasa HealthCare and First Databank (FDB). Broad incumbents are Wolters Kluwer (Medi-Span), Elsevier Clinical Solutions (ClinicalPath / ClinicalKey), Lexicomp (Wolters Kluwer) and Precision Medicine Group. Emerging players are RxRevu (now Clarify), Kailos Genetics (a Kadance company) and DoseMe. PharmGKB (Stanford) is listed as an others.
Does GalenusRx have an API?
No public API is recorded for GalenusRx.
What industry is GalenusRx in?
GalenusRx's product category is Medication Safety Analytics. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLACAKAK, Medication Safety, Pharmacovigilance & Adverse Event Reporting IT. Its NAICS code is 621511 and its SIC code is 8071.